EUCTR2009-016266-90-CZ进行中（未招募）不适用
A randomized, double-blind, placebo-controlled, multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of SAR153191 on top of methotrexate (MTX) in patients with active rheumatoid arthritis who are inadequate responders to MTX therapy - MOBILITY
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,740
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •I 01. Diagnosis of Rheumatoid Arthritis (RA) as defined by the 1987 revised American College of Rheumatology (ACR) criteria with disease duration of no less than 3 months and ACR class I-III.
- •I 02. Patients must be on a stable dose of MTX (10 to 25 mg/week) for a minimum of 6 weeks prior to the Screening Visit and intend to continue for the duration of the study.
- •I 03. Patients must have been treated with, and tolerated, a minimum of 12 weeks treatment with methotrexate (MTX) prior to the inclusion visit.
- •I 04. Patient with moderate to severe active disease defined as:
- •- At least 8 out of 68 joints assessed as painful or tender on motion at both screening and baseline visits, and,
- •- At least 6 out of 66 joints assessed as swollen at both screening and baseline visits,and,
- •- hs C-Reactive Protein >10mg/L at screening visit
- •I 05. Part B only:
- •- At least one locally documented bone erosions (on X-ray) prior to first study drug
- •- Or, anti CCP antibody positive according to screening laboratory tests
- •- Or, positive rheumatoid factor according to screening laboratory tests.
- •I 06. Having signed a written informed consent prior to any procedure related to the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •E 01. Male or female <18 years of age or >75 years
- •E 02. Weight <50kg for men or <45kg for women or >110 kg
- •E 03. Autoimmune disease other than RA or significant systemic involvement
- •E 04. History of or current acute inflammatory joint disease other than RA, or RA diagnosed before the age of 16.
- •E 05. Treatment with oral prednisone or equivalent >10mg per day within 4 weeks prior to the Inclusion Visit or Use of parenteral or intra-articular glucocortisteroids within 4 weeks prior to the Screening Visit
- •E 06. Start treatment or change dose of current treatment with NSAIDs/COX2 inhibitors or oral corticosteroids for 4 weeks prior to baseline.
- •E 07. Current treatment with DMARDS/immunosuppressive agents other than MTX.
- •E 08. Past history of non response to prior therapy with TNF antagonist or a biologic treatment.
- •E 09. Prior therapy with a TNF antagonist or any other biologic agents within 3 months prior to inclusion.
- •E 10. Participation in any clinical research study evaluating another investigational drug or therapy within 60 days or at least 5 half-lives, whichever is longer, of the investigational drug, prior to the Screening Visit
- •E 11. History of malignancy other than carcinoma in-situ of the cervix, or adequately treated, non-metastatic squamous or basal cell carcinoma of the skin within five years prior to Screening Visit. History of lymphoproliferative disease or possible current lymphoproliferative disease.
- •E 12. History of alcohol or drug abuse within the 5 years prior to the Screening Visit.
- •E 13. Have a history or presence of significant other concomitant illness according to the Investigator judgment.
- •E 14. Conditions/situations such as:
- •- Patients with short life expectancy
- •- Patients with conditions/concomitant diseases making them non-evaluable for the
- •primary efficacy endpoint
- •- Requirement for concomitant treatment that could bias primary evaluation
- •- Impossibility to meet specific protocol requirements (e.g. need for hospitalization, etc)
- •- Patient is the Investigator or any sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
- •- Uncooperative or any condition that could make the patient potentially non-compliant with the study procedures
- •E 15. Patients not willing to take folic acid with the MTX dose, to minimize toxicity
- •E 16. Pregnant or breast-feeding women,
- •E 17. Previous exposure to SAR153191
- •E 18. For women of childbearing potential, unwillingness to utilize adequate contraception or not become pregnant during the full course of the study.
- •E 19. Any subject who has had surgery within 4 weeks prior to the Screening Visit or with planned elective surgery.
- •E 20. Patients with a latent or active tuberculosis (TB) defined as:
- •- Any signs or symptoms suggestive of active TB upon medical history or clinical
- •examination.
- •- Subjects with a positive QuantiFERON, TB gold test or tuberculin test (PPD skin test
- •=10mm) at screening. (see Section 10.2).
- •- Chest radiograph within 3 months prior to the inclusion visit.
- •- Subjects with close contact with a person with active tuberculosis.
- •E 21. Patients with a history of resolved Listeria or tuberculosis (unless documented adequately treated).
- •E 22. Fever (=38°C) or persistent chronic or active recurring infection requiring treatment with antibiotics, antivirals, or antifungals within 4 weeks prior to the Screening Visit, or history of frequent recurrent infections unacceptable per
研究者
相似试验
已完成
2 期
A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19NL-OMON51156Molecular Partners AG200
招募中
4 期
Treatment of Verruca Plana by external application of tubeimoside injection: a randomized, double-blind, placebo-controlled, multicenter clinical trial.Flat WartITMCTR2000003368Shaanxi Provincial Hospital of Traditional Chinese Medicine
已完成
2 期
A randomized, double-blind, placebo-controlled, multicenter Phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativaNL-OMON46646InflaRx GmbH4
尚未招募
1 期
Clinical evaluation for traditional Chinese medicine combined with antibiotics in the treatment of bacterial pneumonia in childreBacterial pneumonia in childrenITMCTR1900002538Affiliated Hospital of Changchun University of Traditional Chinese Medicine
招募中
1 期
A randomized, double-blind, placebo-controlled, multicenter clinical study on the efficacy and safety of hongjing-1 in the treatment of impotenceErectile DysfunctionITMCTR2100004505The Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine